# Aspirin-Exacerbated Respiratory Disease

> Aspirin-exacerbated respiratory disease: Samter triad, leukotriene mechanism, desensitisation for NEET-PG Medicine preparation.

- Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/aspirin-exacerbated-respiratory-disease
- Exam / course: NEET-PG · Subject: Medicine
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Aspirin-Exacerbated Respiratory Disease", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/aspirin-exacerbated-respiratory-disease

## Direct answer

The triad of asthma, chronic rhinosinusitis with nasal polyps and respiratory reactions to NSAIDs — aspirin-exacerbated respiratory disease (AERD, Samter's triad) — is not an allergy at all: COX-1 inhibition diverts arachidonic acid into the 5-lipoxygenase pathway, flooding patients with cysteinyl leukotrienes whose hallmark is high urinary LTE4. Adult-onset, usually non-atopic patients progress through polyp regrowth and steroid dependence, and management combines leukotriene modulation, biologics such as dupilumab, and — in selected cases — aspirin desensitisation carried out only in a monitored setting with controlled asthma. That mechanism-and-management pairing is a recurring NEET-PG Medicine theme.

## What you must remember

- Triad: asthma + chronic rhinosinusitis with nasal polyps + NSAID hypersensitivity; adults in their thirties, non-atopic, with a modest female predominance.
- Not IgE-mediated: reactions follow COX-1 inhibition in any NSAID (aspirin, ibuprofen, naproxen), dose-dependent and pharmacological, not allergic.
- Mechanism: arachidonic acid shunted to the 5-lipoxygenase pathway; baseline and post-aspirin urinary LTE4 are markedly elevated.
- Typical reaction 30 minutes to 3 hours after ingestion: profuse rhinorrhoea, nasal congestion, flushing, conjunctival injection, bronchospasm — occasionally severe anaphylactoid events.
- COX-2 selective inhibitors (e.g. celecoxib) are generally tolerated under supervised challenge; paracetamol at moderate doses is usually safe.
- Aspirin desensitisation — ascending oral doses to a maintenance of typically 650 mg twice daily — reduces polyp regrowth, restores smell and cuts steroid courses in responders.
- Desensitisation prerequisites: controlled asthma (FEV1 above about 60–70% of predicted), monitored setting, and uninterrupted daily dosing afterwards, since missing more than a few days loses the desensitised state.
- Adjuncts: leukotriene receptor antagonists (montelukast) or the 5-lipoxygenase inhibitor zileuton; biologics (dupilumab, mepolizumab, omalizumab) now reduce polyp burden and steroid dependence.
- Every reaction involves every COX-1 inhibitor — there is no "safe ibuprofen" in this syndrome.

## How to work through a typical case

A 38-year-old woman with no childhood atopy developed asthma at 30, then anosmia and bilateral nasal polyps requiring two endoscopic sinus operations in three years; last month, one ibuprofen tablet produced streaming nose, flushing and wheeze treated in the emergency department.

Step one: recognise the completed triad — adult-onset asthma plus recurrent polyps plus a classic reaction — and stop calling it "ibuprofen allergy" in the notes; the diagnosis is pharmacological intolerance shared by all COX-1 inhibitors. Step two: characterise the mediator phenotype — she likely has marked eosinophilia, high urinary LTE4, and steroid-dependent disease with rapid polyp regrowth, the AERD signature. Step three: secure the airway and nose first — optimise asthma control with inhaled corticosteroid-long-acting bronchodilator, initiate a leukotriene antagonist or zileuton, and plan polyp management (surgical clearance plus topical steroid irrigations) with biologics such as dupilumab where available and affordable. Step four: counsel on drug safety in concrete terms — no over-the-counter aspirin, ibuprofen, diclofenac, naproxen or ketorolac; paracetamol up to moderate doses for fever and pain; supervised celecoxib challenge if a COX-2 inhibitor is genuinely needed. Step five: discuss aspirin desensitisation once asthma is controlled and the nose is optimised — ascending doses over one to two days in a monitored unit, then lifelong twice-daily aspirin; the benefits (fewer polyp operations, smell regained, steroid reduction) apply only while the daily dose continues, and missed doses beyond a few days require repeat desensitisation.

## Where students slip

First, answering "IgE-mediated aspirin allergy" — the exam explicitly wants the COX-1/leukotriene pharmacology. Second, permitting "occasional ibuprofen" or switching between NSAIDs: every COX-1 inhibitor cross-reacts, and only COX-2 selectivity or paracetamol escape the rule. Third, attempting desensitisation during an asthma exacerbation or with unstable baseline lung function — the contraindication examiners probe. Fourth, forgetting that desensitisation is a state maintained by daily dosing, not a one-time cure. Finally, missing the diagnosis in the "polyps returning after surgery" stem — recurrent polyposis in an adult asthmatic should trigger an explicit NSAID reaction history.

## Frequently asked questions

### What constitutes the Samter triad?
Asthma, chronic rhinosinusitis with nasal polyps, and respiratory reactions to aspirin and other NSAIDs — collectively aspirin-exacerbated respiratory disease.

### Why do NSAIDs trigger reactions in AERD?
Inhibition of COX-1 diverts arachidonic acid to the 5-lipoxygenase pathway, generating excess cysteinyl leukotrienes that cause bronchospasm, rhinorrhoea and flushing; it is pharmacological, not IgE-mediated.

### Which analgesics are generally safe in AERD?
Paracetamol at moderate doses and, after supervised challenge, COX-2 selective inhibitors such as celecoxib; all non-selective NSAIDs cross-react.

### What are the prerequisites for aspirin desensitisation?
Controlled asthma with stable lung function (FEV1 above roughly 60–70% of predicted), a monitored setting with resuscitation access, cleared nasal disease, and commitment to uninterrupted daily aspirin afterwards.

### What benefit does aspirin desensitisation offer?
Reduced nasal polyp regrowth and revision surgery, improved sense of smell, fewer corticosteroid courses, and better asthma control in responsive patients — maintained only while daily dosing continues.